Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Given Consensus Recommendation of “Hold” by Analysts

Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) have been assigned an average rating of “Hold” from the seven ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $1.35.

ADAP has been the subject of several recent research reports. Barclays cut their target price on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an “underweight” rating for the company in a research report on Wednesday, May 14th. Mizuho lowered shares of Adaptimmune Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $1.50 to $0.50 in a research report on Thursday. Wall Street Zen assumed coverage on shares of Adaptimmune Therapeutics in a research report on Friday, May 16th. They issued a “buy” rating for the company. Wells Fargo & Company dropped their price target on shares of Adaptimmune Therapeutics from $1.50 to $1.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 14th. Finally, Scotiabank dropped their price target on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research report on Friday, March 21st.

Hedge Funds Weigh In On Adaptimmune Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ADAP. Invesco Ltd. boosted its position in shares of Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 28,526 shares during the last quarter. Two Sigma Advisers LP lifted its position in Adaptimmune Therapeutics by 492.0% during the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 58,787 shares during the last quarter. Two Sigma Investments LP lifted its position in Adaptimmune Therapeutics by 33.5% during the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 19,146 shares during the last quarter. Virtu Financial LLC lifted its position in Adaptimmune Therapeutics by 21.5% during the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 21,688 shares during the last quarter. Finally, LPL Financial LLC lifted its position in Adaptimmune Therapeutics by 106.5% during the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 94,623 shares during the last quarter. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Stock Performance

Shares of NASDAQ ADAP opened at $0.25 on Friday. The firm has a 50 day moving average of $0.27 and a 200 day moving average of $0.41. The company has a current ratio of 2.02, a quick ratio of 1.79 and a debt-to-equity ratio of 4.24. The firm has a market capitalization of $64.94 million, a price-to-earnings ratio of -0.91 and a beta of 2.24. Adaptimmune Therapeutics has a 12-month low of $0.20 and a 12-month high of $1.48.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). The company had revenue of $7.29 million during the quarter, compared to analyst estimates of $6.55 million. Adaptimmune Therapeutics had a negative net margin of 38.91% and a negative return on equity of 163.73%. On average, research analysts anticipate that Adaptimmune Therapeutics will post -0.14 earnings per share for the current year.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.